Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin for prevention of complications in decompensated liver cirrhosis
ChiCTR2200067252Phase 4Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of rifaximin in Cirrhosis (3 arms), sponsored by Shanghai East Hospital. Primary endpoint: Incidence of overall complications resulting from decompensated liver cirrhosis. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
rifaximin
03
Conditions
Cirrhosis
Beyond the preview
Go deeper on ChiCTR2200067252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067252.